Cantor Fitzgerald Downgrades Gossamer Bio (GOSS) to Neutral

Gossamer Bio, Inc. (NASDAQ:GOSS) is one of the 8 Most Oversold Penny Stocks to Buy Right Now.

On March 23, 2026, Cantor Fitzgerald downgraded Gossamer Bio, Inc. (NASDAQ:GOSS) to Neutral from Overweight without a price target. Cantor Fitzgerald cited the negative Phase 3 PROSERA readout and an unclear regulatory path for seralutinib in pulmonary arterial hypertension, noting it is difficult to have conviction on a path to commercialization.

On March 17, 2026, Gossamer Bio reported Q4 EPS of (21c), compared to the (20c) consensus estimate, with revenue of $13.799M versus $7.52M consensus. CEO Faheem Hasnain said the company is focused on reviewing the PROSERA dataset, engaging with the FDA, and evaluating strategic options, noting the trial “narrowly missed” its primary endpoint but that the data support seralutinib as an active drug in PAH, particularly in more advanced patients.

Earlier in March, H.C. Wainwright lowered its price target on Gossamer Bio to $5 from $10 and maintained a Buy rating, reducing its probability of success for seralutinib in pulmonary arterial hypertension to 50% from 70%.

Gossamer Bio, Inc. (NASDAQ:GOSS) develops seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension.

While we acknowledge the risk and potential of GOSS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GOSS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.